GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reviva Pharmaceuticals Holdings Inc (NAS:RVPH) » Definitions » Preferred Stock

Reviva Pharmaceuticals Holdings (Reviva Pharmaceuticals Holdings) Preferred Stock : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Reviva Pharmaceuticals Holdings Preferred Stock?

Preferred stock is a special equity security that has properties of both equity and debt. Reviva Pharmaceuticals Holdings's preferred stock for the quarter that ended in Mar. 2024 was $0.00 Mil.

The market value of preferred stock needs to be added to the market value of common stocks in the calculation of Enterprise Value. Reviva Pharmaceuticals Holdings's Enterprise Value for the quarter that ended in Mar. 2024 was $93.89 Mil.

In the calculation of book value, the par value of preferred stocks needs to subtracted from total equity. Reviva Pharmaceuticals Holdings's Book Value per Share for the quarter that ended in Mar. 2024 was $-0.05.

Dividends paid to preferred stocks need to be subtracted from net income in the calculation of Earnings per Share (Diluted). Reviva Pharmaceuticals Holdings's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.25.


Reviva Pharmaceuticals Holdings Preferred Stock Historical Data

The historical data trend for Reviva Pharmaceuticals Holdings's Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reviva Pharmaceuticals Holdings Preferred Stock Chart

Reviva Pharmaceuticals Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Preferred Stock
29.07 - - - -

Reviva Pharmaceuticals Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Reviva Pharmaceuticals Holdings Preferred Stock Calculation

Preferred Stock is a special equity security that has properties of both equity and debt. It is generally considered a hybrid instrument. Preferred stock is senior to common stock, but is subordinate to bonds in terms of claim or rights to their share of the assets of the company.

Preferred stock has priority over common stock in the payment of dividends and any payments received when a company liquidates.

Preferred stock comes in many forms. It can be:


Convertible or Non-Convertible
Cumulative or Non-Cumulative
Voting or Non-Voting
Callable or Non-Callable
Maturity Date or No Maturity Date

A preferred stock without a maturity date is called a perpetual preferred stock. These are relatively rare. A good example of perpetual preferred stock is the many series of Public Storage (PSA) preferred shares that trade on the New York Stock Exchange.

Before investing in preferred stock, it is important to know which of the above groups the stock belongs to. Is it convertible or non-convertible? Are dividends cumulative or non-cumulative?

It is also critical that an investor knows what bonds the company has in front of the preferred stock. Bondholders get paid first. So the decision to buy a preferred stock can be similar to the decision to buy a bond. But, remember, the preferred stock of a company with bonds is junior to those bonds.

Unless a preferred stock is convertible, the upside in a preferred stock investment is more limited than in a common stock investment. If a company doubles its earnings, it is usually under no more obligation to double the dividends paid to preferred shareholders than it is to double the interest paid to its bankers and bondholders.So preferred stock is very different from common stock.


Reviva Pharmaceuticals Holdings  (NAS:RVPH) Preferred Stock Explanation

When a company needs capital but does not wish to issue debt, they may sell preferred stocks to investors.

For instance, during the financial crisis of 2008, Goldman Sachs (GS) issued a combination of preferred stock and common stock options for $5 billion of capital to Warren Buffett’s Berkshire Hathaway (BRK.A)(BRK.B). In this deal, Berkshire Hathaway paid $5 billion for 10% cumulative perpetual preferred stock and warrants to buy 43.5 million shares of Goldman Sachs at $115 a share. Goldman Sachs bought back the preferred in 2010. Guess how much money Warren Buffett made in this deal in two years? Read How Much Did Warren Buffett’s Berkshire Hathaway (BRK.B) Make on Its Goldman Sachs (GS) Preferred Stock?

1. The market value of Preferred Stocks needs to be added to the market value of common stocks in the calculation of enterprise value.

Reviva Pharmaceuticals Holdings's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as

2. In the calculation of Book Value, the par value of Preferred Stocks needs to subtracted from total equity.

Reviva Pharmaceuticals Holdings's Book Value per Share for the quarter that ended in Mar. 2024 is calculated as

3. Dividends paid to Preferred Stocks need to be subtracted from net income in the calculation of earnings per share.

Reviva Pharmaceuticals Holdings's Earnings per Share (Diluted) (EPS) for the three months ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Reviva Pharmaceuticals Holdings Preferred Stock Related Terms

Thank you for viewing the detailed overview of Reviva Pharmaceuticals Holdings's Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Reviva Pharmaceuticals Holdings (Reviva Pharmaceuticals Holdings) Business Description

Traded in Other Exchanges
N/A
Address
19925 Stevens Creek Boulevard, Suite 100, Cupertino, CA, USA, 95014
Reviva Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, respiratory, and metabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, 1) Brilaroxazine (RP5063) which is in clinical development and is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and 2) RP1208.
Executives
Purav Patel director 19925 STEVENS CREEK BLVD., SUITE 100, CUPERTINO CA 95014
Narayan Parbhu officer: Chief Financial Officer 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA 95014
Beta Operators Fund, L.p. 10 percent owner 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Vedanta Associates, L.p. 10 percent owner 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Vedanta Partners, Llc 10 percent owner 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Vedanta Associates-r, Lp 10 percent owner 250 WEST 55TH STREET, STE 13D, NEW YORK NY 10019
Parag Saxena director, 10 percent owner 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Rahul Nayar 10 percent owner 250 WEST 55TH STREET, NEW YORK NY 10019
Tenzing Llc director, 10 percent owner 250 WEST 55TH STREET, NEW YORK NY 10019
Laxminarayan Bhat director, 10 percent owner, officer: President and CEO 19925 STEVENS CREEK BLVD., SUITE 100, CUPERTINO CA 95014
Leslie D. Funtleyder director C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Marc Cantillon officer: Chief Medical Officer 19925 STEVENS CREEK BLVD., SUITE 100, CUPPERTINO CA 95014
Richard A Margolin director 19925 STEVENS CREEK BLVD, SUITE 100, CUPPERTINO CA 95014
Glazer Capital, Llc 10 percent owner 250 WEST 55TH STREET, SUITE 30A, NEW YORK NY 10019
Paul J Glazer 10 percent owner 250 WEST 55TH ST, SUITE 30A, NEW YORK NY 10019

Reviva Pharmaceuticals Holdings (Reviva Pharmaceuticals Holdings) Headlines